A Phase 1 interventional study of CT-388 and Placebo in Diabetes, sponsored by Carmot Therapeutics, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Diabetes Mellitus by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Hoffmann-La Roche.
Among the 12 studies in Diabetes Mellitus by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 11th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →None of the 12 studies in Diabetes Mellitus by Hoffmann-La Roche is open now. The open studies under Diabetes Mellitus, anywhere →
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 180 across the 10 interventional studies, 246 across the 1 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Carmot Therapeutics, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Carmot Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Diabetes Mellitus by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SC dose of CT-388
Drug: CT-388
SC dose of placebo matching CT-388 dose
Drug: Placebo
SC dose of CT-388
Drug: CT-388
SC dose of CT-388
Drug: CT-388
Synthetic Peptide
Placebo
Incidence of Treatment-Emergent Adverse Events as assessed by self-report
Safety and tolerability
Time frame: Baseline up to 24 weeks
Area under the concentration versus time curve (AUC)
PK AUC
Time frame: Baseline up to 24 weeks
Maximum observed drug concentration (Cmax)
PK Cmax
Time frame: Baseline up to 24 weeks
Elimination half-life
PK t1/2
Time frame: Baseline up to 24 weeks
Change in mean body weight
PD body weight
Time frame: Baseline up to 24 weeks
Change in mean glucose levels
PD glucose
Time frame: Baseline up to 24 weeks
Change in mean insulin levels
PD insulin
Time frame: Baseline up to 24 weeks
Plan to share: No
Ran from Apr 2021 to primary completion in Jun 2024, 37 months.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 37 months is above that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enicepatide